One-carbon therapeutics AB is discussing the ODIN trial with several leading clinical sites at the upcoming ESMO meeting in Barcelona. The ODIN trial is a first-in-human, first-in-class clinical phase 1/2 trial with MTHFD1/2 inhibitor TH9619 in selected solid cancers.
One-carbon Therapeutics Announces Strategic Collaboration with Tempus to Advance Molecular Insights and Enable Precision Oncology Development of TH9619
Solna, Sweden, March 17h, 2026. One-carbon Therapeutics, a clinical-stage oncology
